CN1318422C - 取代吡唑并嘧啶和噻唑并嘧啶 - Google Patents

取代吡唑并嘧啶和噻唑并嘧啶 Download PDF

Info

Publication number
CN1318422C
CN1318422C CNB028096886A CN02809688A CN1318422C CN 1318422 C CN1318422 C CN 1318422C CN B028096886 A CNB028096886 A CN B028096886A CN 02809688 A CN02809688 A CN 02809688A CN 1318422 C CN1318422 C CN 1318422C
Authority
CN
China
Prior art keywords
pyrimidine
butyl
methyl
aryl
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028096886A
Other languages
English (en)
Chinese (zh)
Other versions
CN1507447A (zh
Inventor
M·格尔拉赫
C·毛尔
U·-P·亚古施
B·松德曼
M·福尔
A·P·伊泽尔曼
M·迪森－德格罗特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2001112197 external-priority patent/DE10112197A1/de
Priority claimed from DE2001153344 external-priority patent/DE10153344A1/de
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Publication of CN1507447A publication Critical patent/CN1507447A/zh
Application granted granted Critical
Publication of CN1318422C publication Critical patent/CN1318422C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB028096886A 2001-03-14 2002-03-13 取代吡唑并嘧啶和噻唑并嘧啶 Expired - Fee Related CN1318422C (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE2001112197 DE10112197A1 (de) 2001-03-14 2001-03-14 Substituierte Pyrazolo- und Thiazolopyrimidine
DE10112197.0 2001-03-14
DE2001153344 DE10153344A1 (de) 2001-10-29 2001-10-29 Verwendung von substituierten Pyrazolopyrimidinen als Liganden von Nucleosid-Transport-Proteinen und/oder von Purinorezeptoren
DE10153344.6 2001-10-29
PCT/EP2002/002722 WO2002072585A2 (de) 2001-03-14 2002-03-13 Substituierte pyrazolo- und thiazolopyrimidine als analgetika

Publications (2)

Publication Number Publication Date
CN1507447A CN1507447A (zh) 2004-06-23
CN1318422C true CN1318422C (zh) 2007-05-30

Family

ID=26008763

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028096886A Expired - Fee Related CN1318422C (zh) 2001-03-14 2002-03-13 取代吡唑并嘧啶和噻唑并嘧啶

Country Status (24)

Country Link
US (1) US7135568B2 (enExample)
EP (2) EP1637533B1 (enExample)
JP (1) JP2004527508A (enExample)
KR (1) KR20030082982A (enExample)
CN (1) CN1318422C (enExample)
AT (2) ATE328886T1 (enExample)
AU (1) AU2002302419B2 (enExample)
BR (1) BR0208244A (enExample)
CA (1) CA2440760C (enExample)
CY (1) CY1105507T1 (enExample)
CZ (1) CZ20032474A3 (enExample)
DE (2) DE50212652D1 (enExample)
DK (1) DK1368355T3 (enExample)
ES (2) ES2263779T3 (enExample)
HU (1) HUP0401211A3 (enExample)
IL (2) IL157895A0 (enExample)
MX (1) MXPA03008291A (enExample)
NO (1) NO20034031L (enExample)
NZ (2) NZ540574A (enExample)
PL (1) PL364388A1 (enExample)
PT (1) PT1368355E (enExample)
RU (1) RU2003129060A (enExample)
SK (1) SK11542003A3 (enExample)
WO (1) WO2002072585A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003265585B2 (en) 2002-08-26 2008-07-03 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
WO2004076450A1 (en) * 2003-02-27 2004-09-10 J. Uriach Y Compañia S.A. Pyrazolopyridine derivates
GB0404434D0 (en) 2004-02-27 2004-03-31 Novartis Ag Organic compounds
WO2005112936A1 (en) * 2004-05-14 2005-12-01 The Regents Of The University Of Michigan Compositions and methods relating to protein kinase inhibitors
TW200618800A (en) * 2004-08-03 2006-06-16 Uriach Y Compania S A J Heterocyclic compounds
EP1736475A1 (en) * 2005-06-21 2006-12-27 Ferrer Internacional, S.A. Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates
KR100838692B1 (ko) 2007-07-11 2008-06-16 한국화학연구원 7-(3′,4′-디알콕시페닐)-4,5,6,7-테트라히드로피라졸로[1,5-ａ]피리미딘 화합물, 이의 제조방법 및 이를 포함하는천식 및 만성폐쇄성 폐질환을 포함한 염증관련 질환,관절염, 아토피 피부염, 암 및 뇌질환의 치료 및 예방을위한 약제학적 조성물
WO2009093210A2 (ru) * 2008-01-24 2009-07-30 Alla Chem, Llc ЗАМЕЩЕННЫЕ ЦИKЛOAЛKAHO[e ИЛИ d]ПИPAЗOЛO[l,5-a]ПИPИMИДИHЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
RU2376291C1 (ru) * 2008-05-07 2009-12-20 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 3,5-ДИАМИНО-4-СУЛЬФОНИЛ-ПИРАЗОЛЫ И 2-АМИНО-3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
RU2369600C1 (ru) * 2008-01-24 2009-10-10 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 4-СУЛЬФОНИЛ-ПИРАЗОЛЫ И 3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ5-HT6 РЕЦЕПТОРОВ, АКТИВНЫЙ КОМПОНЕНТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЛЕКАРСТВЕННОЕ СРЕДСТВО И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
JP5584626B2 (ja) * 2008-01-24 2014-09-03 アンドレイ・アレクサンドロビッチ・イワシェンコ ２−アルキルアミノ−３−（アリールスルホニル）−シクロアルキル［ｅ又はｄ］ピラゾロ［１，５−ａ］ピリミジン−セロトニン５−ＨＴ６受容体アンタゴニスト、その調製の方法及び使用
RU2374249C1 (ru) * 2008-09-17 2009-11-27 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ ЦИКЛОАЛКАНО[е ИЛИ d]ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТ6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
US8618114B2 (en) 2008-10-06 2013-12-31 Andrey Alexandrovich Ivashchenko Substituted 3-arylsulfonyl-pyrazolo[1,5-A]pyrimidines, serotonin 5-HT6 receptor antagonists and methods for the production and use thereof
AR074702A1 (es) * 2008-12-22 2011-02-02 Schering Corp Moduladores de gamma secretasa y composiciones farmaceuticas que los contienen
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
CN102775412B (zh) * 2012-08-21 2013-05-01 四川大学 一种镇静催眠的化合物及其制备方法和用途
CN102977106B (zh) * 2012-12-12 2014-12-10 中国药科大学 一类具有外周镇痛作用的κ阿片受体激动剂
ES2687481T3 (es) * 2013-03-15 2018-10-25 Chromocell Corporation Moduladores del canal de sodio para el tratamiento del dolor
KR20160054570A (ko) * 2013-09-10 2016-05-16 크로모셀 코포레이션 통증과 당뇨병의 치료를 위한 나트륨 통로 조절인자
WO2016123629A1 (en) * 2015-01-30 2016-08-04 Vanderbilt University Indazole and azaindazole substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
AU2016338679B2 (en) 2015-10-16 2021-05-06 Eisai R&D Management Co., Ltd. EP4 antagonists
WO2018133835A1 (en) * 2017-01-20 2018-07-26 National Institute Of Biological Sciences, Beijing Nucleoside analogue regulating mammalian circadian rhythm
WO2018199236A1 (ja) 2017-04-27 2018-11-01 武田薬品工業株式会社 複素環化合物
US10919891B2 (en) * 2017-04-27 2021-02-16 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN113354644B (zh) * 2020-03-04 2023-07-04 烟台药物研究所 一类用作dpp-iv抑制剂的吡唑并嘧啶结构的化合物及应用
CN116023382B (zh) * 2023-02-22 2025-09-23 北京师范大学 一种合成手性四氢吡唑并[1,5-a]嘧啶的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0398283A1 (en) * 1989-05-16 1990-11-22 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
US5426106A (en) * 1992-03-23 1995-06-20 Merck Sharp & Dohme Limited Pyrrolo-pyridazinone derivatives
FR2722786A1 (fr) * 1994-07-20 1996-01-26 Rhone Poulenc Rorer Sa Derives de 4-hydroxy-3-phenyl-indeno(1,2-b)pyridine-2(1h)- one, leur preparation et les medicaments les contenant
US5602144A (en) * 1994-12-15 1997-02-11 Merck Patent Gesellschaft Mit Beschrankter Haftung Thienopyridones
US5789406A (en) * 1994-03-28 1998-08-04 Rhone-Poulenc Rorer S.A. Indeno 1,2-E!pyrazine-4-ones, their preparation and the medicaments containing them

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0264773A1 (en) 1986-10-16 1988-04-27 American Cyanamid Company 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidines
US4847256A (en) * 1986-10-16 1989-07-11 American Cyanamid Company 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines
JP2003288537A (ja) 2000-09-25 2003-10-10 Everyd.Com:Kk 商品宅配システムおよび方法
DE10112197A1 (de) 2001-03-14 2002-09-19 Gruenenthal Gmbh Substituierte Pyrazolo- und Thiazolopyrimidine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0398283A1 (en) * 1989-05-16 1990-11-22 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
US5426106A (en) * 1992-03-23 1995-06-20 Merck Sharp & Dohme Limited Pyrrolo-pyridazinone derivatives
US5789406A (en) * 1994-03-28 1998-08-04 Rhone-Poulenc Rorer S.A. Indeno 1,2-E!pyrazine-4-ones, their preparation and the medicaments containing them
FR2722786A1 (fr) * 1994-07-20 1996-01-26 Rhone Poulenc Rorer Sa Derives de 4-hydroxy-3-phenyl-indeno(1,2-b)pyridine-2(1h)- one, leur preparation et les medicaments les contenant
US5602144A (en) * 1994-12-15 1997-02-11 Merck Patent Gesellschaft Mit Beschrankter Haftung Thienopyridones

Also Published As

Publication number Publication date
WO2002072585A2 (de) 2002-09-19
ATE328886T1 (de) 2006-06-15
CZ20032474A3 (cs) 2003-12-17
NO20034031L (no) 2003-10-21
JP2004527508A (ja) 2004-09-09
BR0208244A (pt) 2004-03-02
US7135568B2 (en) 2006-11-14
WO2002072585A3 (de) 2003-02-20
PT1368355E (pt) 2006-09-29
RU2003129060A (ru) 2005-04-10
HUP0401211A3 (en) 2008-03-28
NO20034031D0 (no) 2003-09-11
CA2440760C (en) 2010-02-09
KR20030082982A (ko) 2003-10-23
EP1637533B1 (de) 2008-08-13
IL157895A (en) 2009-12-24
CY1105507T1 (el) 2010-04-28
HUP0401211A2 (hu) 2004-10-28
US20040127508A1 (en) 2004-07-01
DE50207103D1 (en) 2006-07-20
MXPA03008291A (es) 2003-12-11
ATE404568T1 (de) 2008-08-15
ES2311920T3 (es) 2009-02-16
EP1637533A1 (de) 2006-03-22
PL364388A1 (en) 2004-12-13
ES2263779T3 (es) 2006-12-16
IL157895A0 (en) 2004-03-28
EP1368355B1 (de) 2006-06-07
DK1368355T3 (da) 2006-10-09
CN1507447A (zh) 2004-06-23
NZ528639A (en) 2005-07-29
NZ540574A (en) 2006-11-30
SK11542003A3 (sk) 2004-07-07
HK1061034A1 (en) 2004-09-03
EP1368355A2 (de) 2003-12-10
CA2440760A1 (en) 2002-09-19
AU2002302419B2 (en) 2007-01-18
DE50212652D1 (de) 2008-09-25

Similar Documents

Publication Publication Date Title
CN1318422C (zh) 取代吡唑并嘧啶和噻唑并嘧啶
JP7129420B2 (ja) Ｈｐｋ１阻害剤としてのイソキノリン
KR101499308B1 (ko) 가용성 구아닐레이트 시클라제 활성화제
KR101222330B1 (ko) 아미노-헤테로시클릭 화합물
KR102021159B1 (ko) 트리시클릭 헤테로시클릭 화합물 및 jak 저해제
EP3038466B1 (en) 2,2-difluorodioxolo a2a receptor antagonists
JP5781510B2 (ja) ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
JP2020193211A (ja) Ａ２ａ拮抗薬特性を有するアミノピラジン化合物
CN104884458A (zh) 作为蛋白质激酶抑制剂的稠合杂环化合物
CZ20031777A3 (cs) Triheterocyklické sloučeniny a léčivo na jejich bázi
IL98316A (en) 2-heteroaryl-5-substituted-1-,2, 4-triazolo [1,5a] [1,3,5] triazine-7-amines and 7-heteroaryl-2-substituted-pyrazolo [1,5-a] [1,3,5] triazine-4-amines their preparation and pharmaceutical compositions containing them
JP2004527508A5 (enExample)
EP2077835A2 (en) An alzheimer's disease progression inhibitor containing heterocyclic compound
CN102548995B (zh) 杂环腙化合物以及它们治疗癌症和炎症的用途
JP2023508943A (ja) ジヒドロシクロペンタ－イソキノリン－スルホンアミド誘導体化合物
JP4315678B2 (ja) 置換された３，４−ジヒドロ−ピリド［１，２−ａ］ピリミジン類
DE10153344A1 (de) Verwendung von substituierten Pyrazolopyrimidinen als Liganden von Nucleosid-Transport-Proteinen und/oder von Purinorezeptoren
CN120936610A (zh) 可用于治疗神经障碍和精神障碍的作为毒蕈碱型乙酰胆碱受体m4正向别构调节剂的1,6-萘啶衍生物
CN121241048A (zh) Kcc2增强剂及其用途
TWI602818B (zh) 稠合雜環化合物作爲蛋白激酶抑制劑
DE10112197A1 (de) Substituierte Pyrazolo- und Thiazolopyrimidine
HK1061034B (en) Substituted pyrazolopyrimidines and thiazolopyrimidines
JP2004511485A (ja) 置換された３，４−ジヒドロ−ピリミド［１，２−ａ］ピリミジン類及び３，４−ジヒドロ−ピラジノ［１，２−ａ］ピリミジン類

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070530

Termination date: 20120313